AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment. On September 29, Reuters reported that the company has applied to the US Food and Drug Administration for approval of ORPATHYS-TAGRISSO. But can this potential lung cancer breakthrough meaningfully accelerate AstraZeneca's broader oncology growth story, or will pressure on established medicines limit the upside? Lung Cancer Treatment Opportunity Developed in partnership with HUTCHMED, the combination is designed to treat patients with advanced lung cancer whose disease has progressed during or after treatment with an EGFR-targeted therapy.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.